Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM8ZTPF)

• Drug Name: (S)-Norfluoxetine Drug Info
• Synonyms: 126924-38-7; SEPROXETINE; UNII-25CO3X0R31; (S)-3-PHENYL-3-(4-TRIFLUOROMETHYL-PHENOXY)-PROPYLAMINE; CHEMBL465123; (3S)-3-phenyl-3-[4-(trifluoromethyl)phenoxy]propan-1-amine; 25CO3X0R31; (S)-3-phenyl-3-(4-(trifluoromethyl)phenoxy)propan-1-amine; Seproxetine [INN]; S-Norfluoxetine; AC1MHW5Z; SCHEMBL272873; ZINC4531; CTK8E9555; MolPort-005-941-621; 9173AH; BDBM50254790; AKOS027384574; DB06731; AJ-08214; RT-014029; FT-0673089; NFL_296.1257_14.5; J-005451

Indication

Disease Entry	ICD 11	Status	REF
Discovery agent	N.A.	Investigative	[1]

• Cross-matching ID:
  PubChem CID: 3058751
  ChEBI ID: CHEMBL465123
  CAS Number: CAS 126924-38-7
  TTD Drug ID: DM8ZTPF
  VARIDT Drug ID: DR00906

Molecule-Related Drug Atlas

Drug(s) Targeting Norepinephrine transporter (NET)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[3]
Amitriptyline	DMK7F9S	Depression	6A70-6A7Z	Approved	[4]
Imipramine	DM2NUH3	Depression	6A70-6A7Z	Approved	[5]
Desipramine	DMT2FDC	Attention deficit hyperactivity disorder	6A05.Z	Approved	[3]
Cocaine	DMSOX7I	Anaesthesia	9A78.6	Approved	[6]
Bupropion	DM5PCS7	Depression	6A70-6A7Z	Approved	[7]
Tapentadol hydrochloride	DMXLSH3	Acute pain	MG31	Approved	[8]
Venlafaxine	DMR6QH0	Anxiety disorder	6B00-6B0Z	Approved	[7]
Trimipramine	DM1SC8M	Major depressive disorder	6A70.3	Approved	[9]
Duloxetine	DM9BI7M	Depression	6A70-6A7Z	Approved	[10]

Drug(s) Targeting Serotonin transporter (SERT)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[3]
Amitriptyline	DMK7F9S	Depression	6A70-6A7Z	Approved	[4]
Fluoxetine	DM3PD2C	Bipolar depression		Approved	[11]
Vortioxetine	DM6F1PU	Major depressive disorder	6A70.3	Approved	[12]
Sertraline	DM0FB1J	Coronary heart disease	BA80.Z	Approved	[13]
Cocaine	DMSOX7I	Anaesthesia	9A78.6	Approved	[6]
Bupropion	DM5PCS7	Depression	6A70-6A7Z	Approved	[7]
Citalopram	DM2G9AE	Acute coronary syndrome	BA41	Approved	[11]
Nortriptyline	DM4KDYJ	Depression	6A70-6A7Z	Approved	[11]
Trazodone	DMK1GBJ	Depression	6A70-6A7Z	Approved	[11]

Drug(s) Targeting Dopamine transporter (DAT)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cocaine	DMSOX7I	Anaesthesia	9A78.6	Approved	[6]
Dasotraline	DMLDQFV	Attention deficit hyperactivity disorder	6A05.Z	Approved	[14]
Methylphenidate	DM7SJD6	Attention deficit hyperactivity disorder	6A05.Z	Approved	[15]
Modafinil	DMYILBE	Malignant glioma	2A00.0	Approved	[11]
Phenmetrazine	DMXYTN9	Obesity	5B81	Approved	[16]
Ioflupane i-123	DMNARJT	Parkinson disease	8A00.0	Approved	[17]
DEXMETHYLPHENIDATE HYDROCHLORIDE	DM8WBAH	Attention deficit hyperactivity disorder	6A05.Z	Approved	[18]
Altropane	DMO9WDS	Attention deficit hyperactivity disorder	6A05.Z	Approved	[19]
Amitifadine	DMS1X67	Obesity	5B81	Phase 3	[20]
NAV5001	DMRSI1M	Dementia	6D80-6D86	Phase 3	[19]

Drug(s) Affected By SPARC (SPARC)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[21]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[22]
Cyclophosphamide	DM4O2Z7	Advanced cancer	2A00-2F9Z	Approved	[23]
LY2835219	DM93VBZ	Breast cancer	2C60-2C65	Approved	[24]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[25]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[26]
Palbociclib	DMD7L94	Breast cancer	2C60-2C65	Approved	[24]
Ethanol	DMDRQZU	Chronic pain	MG30	Approved	[27]
Folic Acid	DMEMBJC	Colorectal carcinoma		Approved	[28]
Paclitaxel	DMLB81S	Breast carcinoma		Approved	[29]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Dopamine transporter (DAT)	TTVBI8W	SC6A3_HUMAN	Inhibitor	[1]
Norepinephrine transporter (NET)	TTAWNKZ	SC6A2_HUMAN	Inhibitor	[1]
Serotonin transporter (SERT)	TT3ROYC	SC6A4_HUMAN	Inhibitor	[1]

Drug Off-Target (DOT)

DOT Name	DOT ID	UniProt ID	Interaction	REF
SPARC (SPARC)	OTPN90H0	SPRC_HUMAN	Drug Response	[2]

References

• [1] Stereoselective inhibition of serotonin re-uptake and phosphodiesterase by dual inhibitors as potential agents for depression. Bioorg Med Chem. 2009 Jan 1;17(1):337-43.
• [2] ADReCS-Target: target profiles for aiding drug safety research and application. Nucleic Acids Res. 2018 Jan 4;46(D1):D911-D917. doi: 10.1093/nar/gkx899.
• [3] Augmentation effect of combination therapy of aripiprazole and antidepressants on forced swimming test in mice. Psychopharmacology (Berl). 2009 Sep;206(1):97-107.
• [4] Treatment of comorbid pain with serotonin norepinephrine reuptake inhibitors. CNS Spectr. 2008 Jul;13(7 Suppl 11):22-6.
• [5] Invivo antioxidant status: a putative target of antidepressant action. Prog Neuropsychopharmacol Biol Psychiatry. 2009 Mar 17;33(2):220-8.
• [6] Differential involvement of the norepinephrine, serotonin and dopamine reuptake transporter proteins in cocaine-induced taste aversion. Pharmacol Biochem Behav. 2009 Jul;93(1):75-81.
• [7] Clinically relevant drug interactions with new generation antidepressants and antipsychotics. Ther Umsch. 2009 Jun;66(6):485-92.
• [8] 2008 FDA drug approvals. Nat Rev Drug Discov. 2009 Feb;8(2):93-6.
• [9] Antidepressants suppress production of the Th1 cytokine interferon-gamma, independent of monoamine transporter blockade. Eur Neuropsychopharmacol. 2006 Oct;16(7):481-90.
• [10] Multi-target therapeutics: when the whole is greater than the sum of the parts. Drug Discov Today. 2007 Jan;12(1-2):34-42.
• [11] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
• [12] Radium 223 dichloride for prostate cancer treatment. Drug Des Devel Ther. 2017 Sep 6;11:2643-2651.
• [13] Psychopharmacological treatment of dermatological patients--when simply talking does not help. J Dtsch Dermatol Ges. 2007 Dec;5(12):1101-6.
• [14] Dasotraline for the Treatment of Attention-Deficit/Hyperactivity Disorder: A Randomized, Double-Blind, Placebo-Controlled, Proof-of-Concept Trial in Adults. Neuropsychopharmacology. 2015 Nov;40(12):2745-52.
• [15] Imaging the effects of methylphenidate on brain dopamine: new model on its therapeutic actions for attention-deficit/hyperactivity disorder. Biol Psychiatry. 2005 Jun 1;57(11):1410-5.
• [16] Interaction of the anorectic medication, phendimetrazine, and its metabolites with monoamine transporters in rat brain. Eur J Pharmacol. 2002 Jun 28;447(1):51-7.
• [17] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
• [18] Synthesis and pharmacology of site-specific cocaine abuse treatment agents: restricted rotation analogues of methylphenidate. J Med Chem. 2007 May 31;50(11):2718-31.
• [19] Rapid detection of Parkinson's disease by SPECT with altropane: a selective ligand for dopamine transporters. Synapse. 1998 Jun;29(2):128-41.
• [20] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 927).
• [21] MS4A3-HSP27 target pathway reveals potential for haematopoietic disorder treatment in alimentary toxic aleukia. Cell Biol Toxicol. 2023 Feb;39(1):201-216. doi: 10.1007/s10565-021-09639-4. Epub 2021 Sep 28.
• [22] Transcriptional and Metabolic Dissection of ATRA-Induced Granulocytic Differentiation in NB4 Acute Promyelocytic Leukemia Cells. Cells. 2020 Nov 5;9(11):2423. doi: 10.3390/cells9112423.
• [23] Comparative gene expression analysis of a chronic myelogenous leukemia cell line resistant to cyclophosphamide using oligonucleotide arrays and response to tyrosine kinase inhibitors. Leuk Res. 2007 Nov;31(11):1511-20.
• [24] Biological specificity of CDK4/6 inhibitors: dose response relationship, in vivo signaling, and composite response signature. Oncotarget. 2017 Jul 4;8(27):43678-43691. doi: 10.18632/oncotarget.18435.
• [25] Comparison of HepG2 and HepaRG by whole-genome gene expression analysis for the purpose of chemical hazard identification. Toxicol Sci. 2010 May;115(1):66-79.
• [26] Human embryonic stem cell-derived test systems for developmental neurotoxicity: a transcriptomics approach. Arch Toxicol. 2013 Jan;87(1):123-43.
• [27] Comparison of replicative senescence and stress-induced premature senescence combining differential display and low-density DNA arrays. FEBS Lett. 2005 Jul 4;579(17):3651-9. doi: 10.1016/j.febslet.2005.05.056.
• [28] Folic acid modulates cancer-associated micro RNAs and inflammatory mediators in neoplastic and non-neoplastic colonic cells in a different way. Mol Nutr Food Res. 2017 Dec;61(12). doi: 10.1002/mnfr.201700260. Epub 2017 Nov 9.
• [29] Identification of selective inhibitors of cancer stem cells by high-throughput screening. Cell. 2009 Aug 21;138(4):645-659. doi: 10.1016/j.cell.2009.06.034. Epub 2009 Aug 13.